No abstract available.
Diabetes Mellitus, Type 2/complications ; Female ; Genital Neoplasms, Female/complications/*drug therapy ; Humans ; Metformin/*therapeutic use

Diterpenes, Abietane ; therapeutic use ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Genital Neoplasms, Female ; drug therapy ; Humans

OBJECTIVE: Palonosetron is effective for the management of acute and delayed chemotherapy-induced nausea and vomiting (CINV). While emetogenic carboplatin-based chemotherapy is widely used to treat gynecologic cancers, few studies have evaluated the antiemetic effectiveness of palonosetron in this setting. METHODS: A multicenter, single-arm, open-label phase II trial was conducted to evaluate the safety and effectiveness of palonosetron in controlling CINV in patients with gynecologic cancer. Chemotherapy-naïve patients received intravenous palonosetron (0.75 mg/body) and dexamethasone before the infusion of carboplatin-based chemotherapy on day 1. Dexamethasone was administered (orally or intravenously) on days 2–3. The incidence and severity of CINV were evaluated using the patient-completed Multinational Association of Supportive Care in Cancer Antiemesis Tool and treatment diaries. The primary endpoint was the proportion of patients experiencing complete control (CC) of vomiting, with “no rescue antiemetic medication” and “no clinically significant nausea” or “only mild nausea” in the delayed phase (24–120 hours post-chemotherapy). Secondary endpoints were the proportion of patients with a complete response (CR: “no vomiting” and “no rescue antiemetic medication”) in the acute (0–24 hours), delayed (24–120 hours), and overall (0–120 hours) phases, and CC in the acute and overall phases. RESULTS: Efficacy was assessable in 77 of 80 patients recruited. In the acute and delayed phases, the CR rates the primary endpoint, were 71.4% and 59.7% and the CC rates, the secondary endpoint, were 97.4% and 96.1%, respectively. CONCLUSION: While palonosetron effectively controls acute CINV, additional antiemetic management is warranted in the delayed phase after carboplatin-based chemotherapy in gynecologic cancer patients (Trial registry at UMIN Clinical Trials Registry, UMIN000012806).
Antiemetics ; Carboplatin ; Dexamethasone* ; Drug Therapy* ; Female ; Genital Neoplasms, Female ; Humans ; Incidence ; Japan* ; Nausea* ; Vomiting*

While photodynamic therapy is applied on neoplasm, photosensitisers tend to accumulate in neoplastic tissues. With appropriate wavelength light, it causes photochemical reaction and destructs neoplastic tissues. Its better selection for tumor tissue with effective photochemical reaction, and lower side effect make it widespread application in gynecologic oncology. At present, photodynamic therapy has been used in diagnosing and treating lower genital tract carcinoma in situ, and advanced malignant tumor such as vulval and ovarian carcinoma.
Female ; Genital Neoplasms, Female ; drug therapy ; Hematoporphyrin Derivative ; therapeutic use ; Hematoporphyrin Photoradiation ; Humans ; Ovarian Neoplasms ; drug therapy ; Photochemotherapy ; Photosensitizing Agents ; therapeutic use ; Uterine Cervical Neoplasms ; drug therapy

PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) can cause severe malnutrition. However, relationships between CINV levels, non-pharmacological coping methods, and nutritional status of female cancer patients have rarely been investigated. Therefore, this study aimed to analyze their relationships in gynecologic cancer patients. METHODS: Participants receiving a highly and moderately emetogenic chemotherapy were recruited. The level of CINV was assessed using a numeric rating scale. Coping methods were determined using multiple-choice self-report questionnaires and categorized into seven types for statistical analysis. Nutritional status was evaluated using biochemical and anthropometric parameters. RESULTS: Among all the 485 patients, 200 eligible inpatients were included. Despite the administration of prophylactic antiemetics, 157 patients (78.5%) still experienced CINV, and several used nonmedically recommended coping methods, such as just enduring the symptom or rejecting food intake. A total of 181 patients (90.5%) had nutritional disorders. Although the level of CINV was indirectly related to the occurrence of nutritional disorders, patients who rejected food (β=1.57, p=.023) and did not use physical measures (β= −1.23, p=.041) as coping methods were under the high risk of nutritional disorders. CONCLUSION: Korean gynecologic cancer patients had high levels of CINV and were at high risk of nutritional disorders, which may be related to the use of nonscientific coping methods, possibly due to cultural backgrounds and lack of proper nutritional program. Therefore, developing a culturally appropriate educational program for the cancer patients with CINV is urgently needed.
Antiemetics ; Child ; Drug Therapy ; Eating ; Female ; Genital Neoplasms, Female ; Humans ; Inpatients ; Malnutrition ; Methods* ; Nausea* ; Nutrition Disorders ; Nutritional Status* ; Vomiting*

PURPOSE: This study was to measure the quality of life(QOL) and to identify the related factors in gynecological cancer patients during chemotherapy. METHOD: The subjects of this study were the patients who had undergone a hysterectomy and were admitted for chemotherapy at S university hospital between November 2006 and April 2007. Data was collected from 106 gynecological cancer patients with the use of a structured questionnaire which measured the QOL(FACT-G), body image, the presence of anxiety & depression, uncertainty, and family support. The data was analyzed by the SPSS win 12.0 program. RESULTS: The mean FACT-total score was 62.1(+/-16.7) (range; 26-107). Positive correlations were found between QOL and body image(r= .67, p= .00), and QOL and family support(r= .32, p= .00), whereas there were negative correlations between QOL and anxiety(r= -.54, p= .00), QOL and depression(r= -.70, p= .00), and QOL and uncertainty(r= -.59, p= .00). Fifty seven precent of the variance in subjective overall QOL can be explained by depression, body image, and uncertainty(Adj R2= .57, F=47.00, p= .00). CONCLUSION: Our patients had a relatively low QOL score. Factors significantly affecting quality of life were depression, body image and uncertainty. Nursing interventions, therefore, should be focused on improving QOL in gynecological cancer patients during chemotherapy, particularly so in patients with depression, uncertainty or poor body image.
Anxiety ; Body Image ; Depression ; Drug Therapy* ; Female ; Genital Neoplasms, Female ; Humans ; Hysterectomy ; Nursing ; Quality of Life* ; Surveys and Questionnaires ; Uncertainty

Cervical, endometrial, and ovarian cancers, have both high morbidity and mortality among the gynecologic malignant tumors in Japan. The present study was conducted using both the population-based cancer registry and the gynecologic cancer registry to elucidate the characteristics of gynecologic malignant tumors in Japan. Based on nationwide estimates from the population-based cancer registry in Japan, the morbidities and mortality of cervical, endometrial, and ovarian cancers were obtained and used for analysis. Clinicopathologic factors for cervical cancer, endometrial cancer, ovarian cancer, including age, clinical stage, postsurgical stage, histological type, therapeutic strategy, and prognosis were retrieved from the gynecologic cancer registry published by the Japan Society of Obstetrics and Gynecology and used for analysis. The morbidities of cervical, endometrial, and ovarian cancers were 10,908, 13,606, and 9,384 women in 2012, respectively. The prevalence of endometrial cancer has significantly and consistently been increasing and represents the most common gynecologic malignant tumor in Japan. The mortalities of cervical, endometrial, and ovarian cancers were 2.1, 1.3, and 3.2 per 100,000 in 2012, respectively. In 2014, 52.2% of cervical cancer patients were classified as stage I, 22.5% as stage II, 10.2% as stage III, and 11.2% as stage IV. In addition, 71.9% of endometrial cancer patients were classified as stage I, 6.0% as stage II, 13.3% as stage III, and 7.5% as stage IV. Finally, 43.2% of ovarian cancer patients were classified as stage I, 9.1% as stage II, 27.6% as stage III, and 7.2% as stage IV. Twelve point five percent of ovarian cancer patients received neoadjuvant chemotherapy.
Drug Therapy ; Endometrial Neoplasms ; Female ; Genital Neoplasms, Female ; Gynecology ; Humans ; Japan* ; Mortality ; Obstetrics ; Ovarian Neoplasms ; Prevalence ; Prognosis ; Registries ; Uterine Cervical Neoplasms

Genital tuberculosis involving the ovary in a non-immunocompromised individual is rare. We report a case of coexisting ovarian serous cystadenoma and tuberculosis in a 29-year-old Indian woman. Clinical examination revealed the presence of an abdominal mass suspicious for ovarian neoplasm. Histopathological evaluation revealed ovarian neoplasm and concomitant tuberculosis. To the best of our knowledge, and after an extensive search of the literature, the coexistence of benign ovarian neoplasm and tuberculosis has not been previously documented.
Adult ; Antitubercular Agents ; therapeutic use ; Cystadenoma, Serous ; complications ; surgery ; Female ; Humans ; Ovarian Diseases ; complications ; drug therapy ; surgery ; Ovarian Neoplasms ; complications ; surgery ; Tuberculosis, Female Genital ; complications ; drug therapy ; surgery

In 2014, 9 topics were selected as major advances in clinical research for gynecologic oncology: 2 each in cervical and corpus cancer, 4 in ovarian cancer, and 1 in breast cancer. For cervical cancer, several therapeutic agents showed viable antitumor clinical response in recurrent and metastatic disease: bevacizumab, cediranib, and immunotherapies including human papillomavirus (HPV)-tumor infiltrating lymphocytes and Z-100. The HPV test received FDA approval as the primary screening tool of cervical cancer in women aged 25 and older, based on the results of the ATHENA trial, which suggested that the HPV test was a more sensitive and efficient strategy for cervical cancer screening than methods based solely on cytology. For corpus cancers, results of a phase III Gynecologic Oncology Group (GOG) 249 study of early-stage endometrial cancer with high-intermediate risk factors are followed by the controversial topic of uterine power morcellation in minimally invasive gynecologic surgery. Promising results of phase II studies regarding the effectiveness of olaparib in various ovarian cancer settings are summarized. After a brief review of results from a phase III study on pazopanib maintenance therapy in advanced ovarian cancer, 2 outstanding 2014 ASCO presentations cover the topic of using molecular subtypes in predicting response to bevacizumab. A review of the use of opportunistic bilateral salpingectomy as an ovarian cancer preventive strategy in the general population is presented. Two remarkable studies that discussed the effectiveness of adjuvant ovarian suppression in premenopausal early breast cancer have been selected as the last topics covered in this review.
Biomedical Research/*trends ; Endometrial Neoplasms/drug therapy/pathology/surgery ; Female ; Genital Neoplasms, Female/diagnosis/*therapy ; Humans ; Ovarian Neoplasms/drug therapy/pathology/surgery ; Uterine Cervical Neoplasms/drug therapy/pathology/surgery

Extract of Tripterygium wilfordi (TW) has obvious effects on anti-inflammation, anti-tumor, anti-fertility and immuno-regulation, and it is broadly applied in various clinical departments. Referred to the gynecologic diseases, clinical therapeutic trials of TW on endometriosis, leiomyoma uteri, dysfunctional uterine bleeding and some tumors of women have been carried out, and it can be proved an effective new drug for the treatment of gynecologic diseases.
Anti-Inflammatory Agents ; therapeutic use ; Antineoplastic Agents ; therapeutic use ; Contraceptive Agents, Female ; therapeutic use ; Drugs, Chinese Herbal ; therapeutic use ; Endometriosis ; drug therapy ; Female ; Genital Diseases, Female ; drug therapy ; Genital Neoplasms, Female ; drug therapy ; Humans ; Immunologic Factors ; therapeutic use ; Leiomyoma ; drug therapy ; Metrorrhagia ; drug therapy ; Tripterygium